


PIONEER-HF

#AHA18



Trial description: Patients hospitalized with acute decompensated heart failure (ADHF) were randomized in a 1:1 fashion to either sacubitril/valsartan or enalapril. Patients were followed for 8 weeks.



RESULTS

- Primary endpoint, time-averaged reduction in NT-proBNP: sacubitril/valsartan vs. enalapril: -46.7% vs. -25.3%, p < 0.001
- Worsening renal function: 13.6% vs. 14.7%, p > 0.05, symptomatic hypotension: 15.0% vs. 12.7%, p > 0.05
- Rehospitalization for HF: 8.0% vs. 13.8%, p < 0.05

CONCLUSIONS

- Sacubitril/valsartan reduced NT-proBNP more than enalapril among patients with ADHF; noted as early as 1 week after drug initiation
- Although not powered for clinical endpoints, a reduction in rehospitalization for HF was noted

Velazquez EJ, et al. N Engl J Med 2018;Nov 11:[Epub]